Hims & Hers (HIMS) stock is drawing attention ahead of its Q3 earnings as the company expands into the booming weight-loss drug market. Yesterday, it announced plans to roll out new GLP-1 “microdosing treatments,” expanding its push into lower-cost versions of Novo Nordisk’s (NVO) blockbuster weight-loss drugs like Ozempic and Wegovy. Investors are watching closely to see if this move can drive revenue growth and give HIMS stock a lift in the coming quarters.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
For context, Hims & Hers Health provides accessible healthcare products and services, including prescription medications and wellness products. The company’s new GLP-1 push could spark fresh investor interest ahead of its Q3 results. Hims has rapidly gained market share, operating in a legal gray zone with its compounded weight-loss drugs. However, with regulatory changes and rising competition, it remains to be seen whether this momentum can translate into a meaningful boost for HIMS stock.
Hims Launches GLP-1 Microdosing Treatment Plans
On Wednesday, Hims announced it will start offering GLP-1 “microdosing treatments.” Notably, microdosing GLP-1s means using smaller-than-usual doses, often to cut costs or minimize side effects. However, Hims promotes it as a way to support overall “metabolic health.”
The company further stated that while GLP-1 microdosing is still a new approach that needs more research, early studies indicate these treatments could offer benefits beyond just weight management. These treatments will be offered not only to patients with a high BMI but also to those with other metabolic health risks, such as sleep apnea or high blood pressure.
Hims currently sells compounded semaglutide, which is the same active ingredient found in Wegovy, at doses comparable to Novo’s versions. Now, the company says its healthcare providers will also offer GLP-1 microdosing plans, which use different, likely lower doses than those made by Novo. The new microdosing plan will be priced the same as its other compounded GLP-1 offerings, at $1,200 for a six-month package paid upfront.
What Analysts Expect from HIMS’ Q3 Earnings
The company is set to report its Q3 2025 results on November 3, with investors looking for signs of renewed revenue momentum after growth slowed in the previous quarter. Below is the screenshot of the company revenue growth over the last few quarters.
Looking ahead, Wall Street analysts expect Hims to report Q3 earnings of $0.09 per share, down from $0.32 in the same quarter last year. Revenue, however, is projected to climb to $580.24 million, marking growth of more than 40% year over year.
Is HIMS Stock a Good Buy?
Overall, Wall Street analysts have a Hold consensus rating on HIMS stock based on two Buys, eight Holds, and two Sells assigned in the last three months. The average HIMS stock price target of $49.75 implies an upside of 6.7% from the current trading level.
